[1]
|
Sookoian, S., Pirola, C.J., et al. (2015) Liver Enzymes, Metabolomics and Genome-Wide Association Studies: From Systems Biology to the Personalized Medicine. World Journal of Gastroenterology, 21, 711-725.
https://doi.org/10.3748/wjg.v21.i3.711
|
[2]
|
Kwo, P.Y., Cohen, S.M., Lim, J.K., et al. (2017) ACG Clinical Guide-line: Evaluation of Abnormal Liver Chemistries. The American Journal of Gastroenterology, 112, 18-35. https://doi.org/10.1038/ajg.2016.517
|
[3]
|
Giannini, E.G., Testa, R., Savarino, V., et al. (2005) Liver Enzyme Al-teration: A Guide for Clinicians. CMAJ, 172, 367- 379. https://doi.org/10.1503/cmaj.1040752
|
[4]
|
Horiuchi, S., Kamimoto, Y. and Morino, Y. (1985) Hepatic Clearance of Rate Liver Aspartate Aminotransferase Isoenzymes: Evidence for Endocytotic Uptake via Different Binding Sites on Sinusoidal Liver Cells. Hepatology, 5, 376- 382. https://doi.org/10.1002/hep.1840050306
|
[5]
|
Smit, M.J., Wijnholds, J., Duursma, A.M., et al. (1986) Plasma Clearance of Mitochondrial Aspartate Aminotransferase in the Rate: Competition with Mitochondrial Malate Dehydro-genase. Biomedica Biochimica Acta, 45, 1557-1561.
|
[6]
|
Wieme, R.J., Demeulenaere, L., et al. (1970) Enzyme Assays in Liver Disease. Journal of Clinical Pathology, 4, 51-59.
https://doi.org/10.1136/jcp.s1-4.1.51
|
[7]
|
Reutemann, B., Gordon, F.D., et al. (2023) Evaluation of the Patient with Markedly Abnormal Liver Enzymes. Clinics in Liver Disease, 27, 1-16. https://doi.org/10.1016/j.cld.2022.08.007
|
[8]
|
Kalas, M.A., Chavez, L., Leon, M., et al. (2021) Abnormal Liver Enzymes: A Review for Clinicians. World Journal of Hepatology, 13, 1688-1698. https://doi.org/10.4254/wjh.v13.i11.1688
|
[9]
|
Kwak, J.Y., Kim, H.G., Han, J.H., et al. (2023) Association of the Etiology and Peak Level of Markedly Elevated Aminotransferases with Mortality: A Multicenter Study. Hepatology Communications, 7, e0149.
https://doi.org/10.1097/HC9.0000000000000149
|
[10]
|
Dufour, D.R., Lott, J.A., Nolte, F.S., et al. (2000) Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Mon-itoring. Clinical Chemistry, 46, 2050-2068.
https://doi.org/10.1093/clinchem/46.12.2050
|
[11]
|
Ramachandran, A., Jaeschke, H., et al. (2019) Acetaminophen Hepatotoxicity. Seminars in Liver Disease, 39, 221-234.
https://doi.org/10.1055/s-0039-1679919
|
[12]
|
Chalasani, N., Fontana, R.J., Bonkovsky, H.L., et al. (2008) Causes, Clinical Features, and Outcomes from a Prospective Study of Drug Induced Liver Injury in the United States. Gastroen-terology, 135, 1924-1934.
https://doi.org/10.1053/j.gastro.2008.09.011
|
[13]
|
Navarro, V.J., Khan, I., Björnsson, E., et al. (2017) Liver Injury from Herbal and Dietary Supplements. Hepatology, 65, 363-373. https://doi.org/10.1002/hep.28813
|
[14]
|
Teschke, R., Eickhoff, A., et al. (2015) Herbal Hepatotoxicity in Traditional and Modern Medicine: Actual Key Issues and New Encouraging Steps. Frontiers in Pharmacology, 6, Article No. 72. https://doi.org/10.3389/fphar.2015.00072
|
[15]
|
(2019) EASL Clinical Practice Guidelines: Drug-Induced Liver In-jury. Journal of Hepatology, 70, 1222-1261.
https://doi.org/10.1016/j.jhep.2019.02.014
|
[16]
|
Devarbhavi, H., Aitha, G.L., Treeprasertsuk, S., et al. (2021) Drug-Induced Liver Injury: Asia Pacific Association of Study of Liver Consensus Guidelines. Hepatology International, 15, 258-282.
https://doi.org/10.1007/s12072-021-10144-3
|
[17]
|
Kleiner, D.E., et al. (2017) The Histopathological Evaluation of Drug-Induced Liver Injury. Histopathology, 70, 81-93.
https://doi.org/10.1111/his.13082
|
[18]
|
Suzuki, A., Brunt, E.M., Kleiner, D.E., et al. (2011) The Use of Liver Bi-opsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis versus Drug-Induced Liver Injury. Hepatology, 54, 931-939.
https://doi.org/10.1002/hep.24481
|
[19]
|
Kleiner, D.E., Chalasani, N.P., Lee, W.M., et al. (2014) Hepatic Histologi-cal Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations. Hepatology, 59, 661-670.
https://doi.org/10.1002/hep.26709
|
[20]
|
Björnsson, E., Kalaitzakis, E., Olsson, R., et al. (2007) The Impact of Eo-sinophilia and Hepatic Necrosis on Prognosis in Patients with Drug-Induced Liver Injury. Alimentary Pharmacology & Therapeutics, 25, 1411-1421.
https://doi.org/10.1111/j.1365-2036.2007.03330.x
|
[21]
|
Bonkovsky, H.L., Kleiner, D.E., Gu, J., et al. (2017) Clin-ical Presentations and Outcomes of Bile Duct Loss Caused by Drugs and Herbal and Dietary Supplements. Hepatology, 65, 1267-1277. https://doi.org/10.1002/hep.28967
|
[22]
|
Aithal, G.P., Watkins, P.B. andrade, R.J., et al. (2011) Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology & Therapeutics, 89, 806-815. https://doi.org/10.1038/clpt.2011.58
|
[23]
|
Fontana, R.J., Seeff, L.B., et al. (2010) Standardization of No-menclature and Causality Assessment in Drug-Induced Liver Injury: Summary of a Clinical Research Workshop. Hepa-tology, 52, 730-742. https://doi.org/10.1002/hep.23696
|
[24]
|
Fontana, R.J. and Bari, K. (2017) Acute Liver Failure. In: Schiff, E.R., Maddrey, W.C. and Reddy, K.R., Eds., Schiff’s Diseases of the Liver, John Wiley & Sons, Hoboken, 411-431. https://doi.org/10.1002/9781119251316.ch17
|
[25]
|
Mallat, A., Zafrani, E.S., Metreau, J.M., et al. (1997) Terbinafine-Induced Prolonged Cholestasis with Reduction of Interlobular Bile Ducts. Digestive Diseases and Sciences, 42, 1486-1488. https://doi.org/10.1023/A:1018870828038
|
[26]
|
Lheureux, P.E.R., Penaloza, A., Zahir, S., et al. (2005) Science Review: Carnitine in the Treatment of Valproic Acid-Induced Toxicity—What Is the Evidence? Critical Care, 9, 431-440. https://doi.org/10.1186/cc3742
|
[27]
|
Lheureux, P.E.R., Hantson, P., et al. (2009) Carnitine in the Treatment of Valproic Acid-Induced Toxicity. Clinical Toxicology (Phila), 47, 101-111. https://doi.org/10.1080/15563650902752376
|
[28]
|
Ohtani, Y., Endo, F., Matsuda, I., et al. (1982) Carnitine Defi-ciency and Hyperammonemia Associated with Valproic Acid Therapy. The Journal of Pediatrics, 101, 782-785. https://doi.org/10.1016/S0022-3476(82)80320-X
|
[29]
|
Bohan, T.P., Helton, E., McDonald, I., et al. (2001) Effect of L-Carnitine Treatment for Valproate-Induced Hepatotoxicity. Neurology, 56, 1405-1409. https://doi.org/10.1212/WNL.56.10.1405
|
[30]
|
Coulepis, A.G., Locarnini, S.A., Westaway, E.G., et al. (1982) Bi-ophysical and Biochemical Characterization of Hepatitis A Virus. Intervirology, 18, 107-127. https://doi.org/10.1159/000149314
|
[31]
|
Coulepis, A.G. anderson, B., et al. (1987) Hepatitis A. Advances in Virus Research, 32, 129-169.
https://doi.org/10.1016/S0065-3527(08)60476-5
|
[32]
|
Odenwald, M.A., Paul, S., et al. (2022) Viral Hepatitis: Past, Present, and Future. World Journal of Gastroenterology, 28, 1405-1429. https://doi.org/10.3748/wjg.v28.i14.1405
|
[33]
|
Cuthbert, J.A., et al. (2001) Hepatitis A: Old and New. Clinical Mi-crobiology Reviews, 14, 38-58.
https://doi.org/10.1128/CMR.14.1.38-58.2001
|
[34]
|
Ganem, D., Prince, A.M., et al. (2004) Hepatitis B Virus In-fection—Natural History and Clinical Consequences. The New England Journal of Medicine, 350, 1118-1129. https://doi.org/10.1056/NEJMra031087
|
[35]
|
Terrault, N.A., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. https://doi.org/10.1002/hep.29800
|
[36]
|
Zignego, A.L., et al. (1990) Amplification of Hepatitis Delta Virus RNA Sequences by Polymerase Chain Reaction: A Tool for Viral Detection and Cloning. Molecular and Cellular Probes, 4, 43-51.
https://doi.org/10.1016/0890-8508(90)90038-2
|
[37]
|
Rosen, H.R., et al. (2011) Clinical Practice. Chronic Hepatitis C Infection. The New England Journal of Medicine, 364, 2429-2438. https://doi.org/10.1056/NEJMcp1006613
|
[38]
|
Armstrong, G.L., Wasley, A., et al. (2006) The Prevalence of Hepa-titis C Virus Infection in the United States, 1999 through 2002. Annals of Internal Medicine, 144, 705-714.
https://doi.org/10.7326/0003-4819-144-10-200605160-00004
|
[39]
|
(2013) Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. Morbidity and Mortality Weekly Report, 62, 362-365.
|
[40]
|
Nimgaonkar, I., Ding, Q., et al. (2018) Hepatitis E Virus: Advances and Challenges. Nature Reviews Gastroenterology & Hepatology, 15, 96-110. https://doi.org/10.1038/nrgastro.2017.150
|
[41]
|
Zhang, J., Zhang, X.F., Huang, S.J., et al. (2015) Long-Term Efficacy of a Hepatitis E Vaccine. The New England Journal of Medicine, 372, 914-922. https://doi.org/10.1056/NEJMoa1406011
|
[42]
|
Hewlett, G., Hallenberger, S., Rübsamen-Waigmann, H., et al. (2004) Antivirals against DNA Viruses (Hepatitis B and the Herpes Viruses). Current Opinion in Pharmacology, 4, 453-464. https://doi.org/10.1016/j.coph.2004.06.004
|
[43]
|
Kwak, J.Y., et al. (2023) Association of the Etiology and Peak Level of Markedly Elevated Aminotransferases with Mortality: A Multicenter Study. Hepatology Communications, 7, e0149.
https://doi.org/10.1097/HC9.0000000000000149
|
[44]
|
Breu, A.C., Patwardhan, V.R., Nayor, J., et al. (2019) A Multicenter Study into Causes of Severe Acute Liver Injury. Clinical Gastroenterology and Hepatology, 17, 1201-1203. https://doi.org/10.1016/j.cgh.2018.08.016
|
[45]
|
Gibson, P.R. and Dudley, F.J. (1984) Ischemic Hepatitis: Clinical Features, Diagnosis and Prognosis. Australian and New Zealand Journal of Medicine, 14, 822-825. https://doi.org/10.1111/j.1445-5994.1984.tb03780.x
|
[46]
|
Gitlin, N. and Serio, K.M. (1992) Ischemic Hepatitis: Widening Horizons. The American Journal of Gastroenterology, 87, 831-836.
|
[47]
|
Shribman, S., Poujois, A., Band-mann, O., et al. (2021) Wilson’s Disease: Update on Pathogenesis, Biomarkers and Treatments. Journal of Neurology, Neurosurgery and Psychiatry, 92, 1053-1061.
https://doi.org/10.1136/jnnp-2021-326123
|
[48]
|
Gu, M., Cooper, J.M., Butler, P., et al. (2000) Oxida-tive-Phosphorylation Defects in Liver of Patients with Wilson’s Disease. The Lancet, 356, 469-474. https://doi.org/10.1016/S0140-6736(00)02556-3
|
[49]
|
Bandmann, O., Weiss, K.H., Kaler, S.G., et al. (2015) Wil-son’s Disease and Other Neurological Copper Disorders. The Lancet Neurology, 14, 103-113. https://doi.org/10.1016/S1474-4422(14)70190-5
|
[50]
|
Yuan, X.Z., Yang, R.M., Wang, X.P., et al. (2021) Man-agement Perspective of Wilson’s Disease: Early Diagnosis and Individualized Therapy. Current Neuropharmacology, 19, 465-485.
https://doi.org/10.2174/1570159X18666200429233517
|
[51]
|
Członkowska, A., Litwin, T., Dusek, P., et al. (2018) Wilson Disease. Nature Reviews Disease Primers, 4, Article No. 21. https://doi.org/10.1038/s41572-018-0018-3
|
[52]
|
Eisenbach, C., Sieg, O., Stremmel, W., et al. (2007) Diagnostic Criteria for Acute Liver Failure Due to Wilson Disease. World Journal of Gastroenterology, 13, 1711-1714. https://doi.org/10.3748/wjg.v13.i11.1711
|
[53]
|
Ostapowicz, G., Fontana, R.J., et al. (2002) Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States. Annals of Internal Medicine, 137, 947-954.
https://doi.org/10.7326/0003-4819-137-12-200212170-00007
|
[54]
|
(2012) EASL Clinical Practice Guidelines: Wilson’s Disease. Journal of Hepatology, 56, 671-685.
https://doi.org/10.1016/j.jhep.2011.11.007
|
[55]
|
Ferenci, P., Caca, K., Loudianos, G., et al. (2003) Diagnosis and Phenotypic Classification of Wilson Disease. Liver International, 23, 139-142. https://doi.org/10.1034/j.1600-0676.2003.00824.x
|
[56]
|
Ferenci, P., Steindl-Munda, P., Vogel, W., et al. (2005) Diagnostic Value of Quantitative Hepatic Copper Determination in Patients with Wilson’s Disease. Clinical Gastroenter-ology and Hepatology, 3, 811-818.
https://doi.org/10.1016/S1542-3565(05)00181-3
|
[57]
|
Roberts, E.A., Schilsky, M.L., et al. (2008) Diagnosis and Treatment of Wilson Disease: An Update. Hepatology, 47, 2089-2111. https://doi.org/10.1002/hep.22261
|
[58]
|
Dzieżyc, K., Litwin, T., Chabik, G., et al. (2014) Families with Wilson’s Disease in Subsequent Generations: Clinical and Genetic Analysis. Movement Disorders, 29, 1828-1832. https://doi.org/10.1002/mds.26057
|
[59]
|
Schilsky, M.L., et al. (1994) Liver Transplantation for Wilson’s Disease: Indications and Outcome. Hepatology, 19, 583-587. https://doi.org/10.1002/hep.1840190307
|
[60]
|
Bellary, S., Hassanein, T., et al. (1995) Liver Transplantation for Wilson’s Disease. Journal of Hepatology, 23, 373- 381. https://doi.org/10.1016/0168-8278(95)80194-4
|
[61]
|
Ahmad, A., Torrazza-Perez, E., Schilsky, M.L., et al. (2017) Liver Transplantation for Wilson Disease. In: Handbook of Clinical Neurology, Vol. 142, Elsevier, Amsterdam, 193-204. https://doi.org/10.1016/B978-0-444-63625-6.00016-1
|
[62]
|
Aydinli, M., Bayraktar, Y., et al. (2007) Budd-Chiari Syndrome: Etiology, Pathogenesis and Diagnosis. World Journal of Gastroenterology, 13, 2693-2696. https://doi.org/10.3748/wjg.v13.i19.2693
|
[63]
|
(2016) EASL Clinical Practice Guidelines: Vascular Diseases of the Liver. Journal of Hepatology, 64, 179-202.
https://doi.org/10.1016/j.jhep.2015.07.040
|
[64]
|
Janssen, H.L.A., Garcia-Pagan, J.C., Elias, E., et al. (2003) Budd-Chiari Syndrome: A Review by an Expert Panel. Journal of Hepatology, 38, 364-371. https://doi.org/10.1016/S0168-8278(02)00434-8
|
[65]
|
Hernández-Guerra, M., Turnes, J., Rubinstein, P., et al. (2004) PTFE-Covered Stents Improve TIPS Patency in Budd- Chiari Syndrome. Hepatology, 40, 1197-1202. https://doi.org/10.1002/hep.20436
|
[66]
|
Grus, T., Lambert, L., Grusová, G., et al. (2017) Budd-Chiari Syndrome. Prague Medical Report, 118, 69-80.
https://doi.org/10.14712/23362936.2017.6
|
[67]
|
Murad, S.D., Plessier, A., Hernandez-Guerra, M., et al. (2009) Etiology, Management, and Outcome of the Budd- Chiari Syndrome. Annals of Internal Medicine, 151, 167-175.
https://doi.org/10.7326/0003-4819-151-3-200908040-00004
|
[68]
|
DeLeve, L.D., Valla, D.C., et al. (2009) Vascular Disorders of the Liver. Hepatology, 49, 1729-1764.
https://doi.org/10.1002/hep.22772
|
[69]
|
Northup, P.G., Garcia-Pagan, J.C., Garcia-Tsao, G., et al. (2021) Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Practice Guid-ance by the American Association for the Study of Liver Diseases. Hepatology, 73, 366-413. https://doi.org/10.1002/hep.31646
|
[70]
|
Jones, R.J., Lee, K.S., Beschorner, W.E., et al. (1987) Venoocclusive Dis-ease of the Liver Following Bone Marrow Transplantation. Transplantation, 44, 778-783. https://doi.org/10.1097/00007890-198712000-00011
|
[71]
|
Mack, C.L., Adams, D., Assis, D.N., et al. (2020) Di-agnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology, 72, 671-722. https://doi.org/10.1002/hep.31065
|
[72]
|
Kim, B.H., Choi, H.Y., Ki, M., et al. (2017) Population-Based Prevalence, Incidence, and Disease Burden of Autoimmune Hepatitis in South Korea. PLOS ONE, 12, e0182391. https://doi.org/10.1371/journal.pone.0182391
|
[73]
|
Takahashi, A., Arinaga-Hino, T., Ohira, T., et al. (2017) Auto-immune Hepatitis in Japan: Trends in a Nationwide Survey. Journal of Gastroenterology, 52, 631-640. https://doi.org/10.1007/s00535-016-1267-0
|
[74]
|
Kim, B.H., Kim, Y.J., et al. (2013) Clinical Features of Autoim-mune Hepatitis and Comparison of Two Diagnostic Criteria in Korea: A Nationwide, Multicenter Study. Journal of Gas-troenterology and Hepatology, 28, 128-134.
https://doi.org/10.1111/j.1440-1746.2012.07292.x
|
[75]
|
Muratori, P., Carbone, M., Stangos, G., et al. (2018) Clin-ical and Prognostic Implications of Acute Onset of Autoimmune Hepatitis: An Italian Multicentre Study. Digestive and Liver Disease, 50, 698-702.
https://doi.org/10.1016/j.dld.2018.02.015
|
[76]
|
(2022) Guidelines on the Diagnosis and Management of Autoim-mune Hepatitis (2021). Chinese Journal of Hepatology, 30, 482-492.
|
[77]
|
Lemos-Bonotto, M.D., Valle-Tovo, C., et al. (2018) A Systematic Review and Meta-Analysis of Second-Line Immunosuppressants for Autoimmune Hepatitis Treat-ment. European Journal of Gastroenterology & Hepatology, 30, 212- 216. https://doi.org/10.1097/MEG.0000000000001019
|
[78]
|
Nicoll, A.J., Roberts, S.K., Lim, R., et al. (2019) Beneficial Response to Mycophenolate Mofetil by Patients with Autoimmune Hepatitis Who Have Failed Standard Therapy, Is Pre-dicted by Older Age and Lower Immunoglobulin G and INR Levels. Alimentary Pharmacology & Therapeutics, 49, 1314-1322. https://doi.org/10.1111/apt.15248
|
[79]
|
Bangaru, S., Thiele, D., Sreenarasimhaiah, J., et al. (2017) Se-vere Elevation of Liver Tests in Choledocholithiasis: An Uncommon Occurrence with Important Clinical Implications. Journal of Clinical Gastroenterology, 51, 728-733.
https://doi.org/10.1097/MCG.0000000000000608
|
[80]
|
Björnsson, H.K., Olafsson, S., Bergmann, O.M., et al. (2016) A Prospective Study on the Causes of Notably Raised Alanine Aminotransferase (ALT). Scandinavian Journal of Gastroenterology, 51, 594-600.
https://doi.org/10.3109/00365521.2015.1121516
|
[81]
|
Björnsson, H.K., Björnsson, E.S., et al. (2019) A Significant Proportion of Patients with Choledocholithiasis Have Markedly Elevated Alanine Aminotransferase. Scandinavian Jour-nal of Gastroenterology, 54, 1155-1159.
https://doi.org/10.1080/00365521.2019.1657177
|
[82]
|
Huh, C.W., Jang, S.I., Lim, B.J., et al. (2016) Clinicopatho-logical Features of Choledocholithiasis Patients with High Aminotransferase Levels without Cholangitis: Prospective Comparative Study. Medicine (Baltimore), 95, e5176.
https://doi.org/10.1097/MD.0000000000005176
|
[83]
|
Souza, M.E., et al. (1990) Serum Transaminase Levels in the Acute Phase of Chronic Extrahepatic Cholestasis. Brazilian Journal of Medical and Biological Research, 23, 995-997.
|
[84]
|
Aronsen, K.F., et al. (1961) Liver Function Studies during and after Complete Extra-Hepatic Biliary Ob-struction in the Dog. Acta chirurgica Scandinavica Supplementum, 275, 1-114.
|